regadenoson has been researched along with Arteriosclerosis, Coronary in 82 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (7.32) | 29.6817 |
2010's | 55 (67.07) | 24.3611 |
2020's | 21 (25.61) | 2.80 |
Authors | Studies |
---|---|
Ahmed, AI; Al-Mallah, MH; Alahdab, F; El Nihum, LI; Han, Y; Nabi, F; Saad, JM | 1 |
Bromberger, B; Brzezinski, M; Calabrese, DR; Kukreja, J | 1 |
Fahed, AC; Grewal, S; Osborne, MT; Qamar, I; Tawakol, A; Weiner, R | 1 |
Dugan, E; Jaber, WA; Parizher, G | 1 |
Bartenstein, P; Bauer, M; Behr, J; Huber, BC; Kneidinger, N; Leuschner, G; Massberg, S; Milger, K; Munker, D; Neurohr, C; Schiopu, SRI; Todica, A; Zacherl, M | 1 |
Ahmed, A; Ahmed, D; Al-Mallah, M; Alali Alfaris, M; Alharthi, M; Aljizeeri, A; Alsaileek, A; Elneama, A; Farea, J; Suliman, I | 1 |
Reyes, E; Richard Underwood, S | 1 |
Bayer, RR; De Cecco, CN; Duguay, TM; Jacobs, BE; Johnson, AA; Litwin, SE; Nance, JW; Schoepf, UJ; Suranyi, P; Tesche, C; van Assen, M; Varga-Szemes, A | 1 |
Demkow, M; Kępka, C; Kruk, M; Marczak, M; Miłosz-Wieczorek, B; Oleksiak, A; Śpiewak, M | 1 |
Araujo Silva, B; Bortolotto, AL; Gervino, EV; Hauser, TH; Marum, AA; Medeiros, SA; Nearing, BD; Pedreira, GC; Tessarolo Silva, F; Verrier, RL | 1 |
Arif, AW; Doukky, R; Khan, MS | 1 |
Kero, T; Knuuti, J; Lagerqvist, B; Lubberink, M; Pikkarainen, E; Saraste, A; Sörensen, J | 1 |
Caobelli, F; Clerc, OF; Frey, SM; Haaf, P; Honegger, U; Zellweger, MJ | 1 |
Ananthasubramaniam, K; Kitt, TM; Kristy, RM; Saval, M; Spalding, JR; Van Harn, M; Xu, Y | 1 |
Adluru, G; Bieging, ET; Chang, L; DiBella, E; Haider, I; Jensen, L; Likhite, D; McGann, CJ; Shaaban, A; Suksaranjit, P; Wilson, BD | 1 |
Kaandorp, TAM; Kuijpers, D; Oudkerk, M; van der Harst, P; van Dijk, R; van Dijkman, PRM; Vliegenthart, R | 1 |
Howe, C; Kumar, G; Lee, JZ; Lee, KS; Low, SW; Nguyen, T; Nyotowidjojo, I; Pinto, D; Singh, N | 1 |
Andrikopoulou, E; Bajaj, NS; Brice, L; Doppalapudi, H; Hage, FG; Iskandrian, AE; Morgan, CJ | 1 |
Balfour, PC; Bourque, J; Epstein, FH; Gonzalez, JA; Kramer, CM; Kuruvilla, S; Mathew, R; Meyer, CH; Pan, J; Salerno, M; Shaw, PW; Taylor, AM; Yang, Y; Zorach, B | 1 |
Gebker, R; Hireche-Chikaoui, H; Kelle, S; Pieske, B; Schnackenburg, B; Stoiber, L | 1 |
Arai, AE; Chen, MY; Conn, HM; Greve, AM; Hsu, LY; Patricia Bandettini, W; Shanbhag, SM; Ta, AD; Winkler, S | 1 |
Cao, JJ; David Cooke, C; Nichols, KJ; Palestro, CJ; Van Tosh, A; Votaw, JR | 1 |
Bönner, F; Heimann, M; Jung, C; Kelm, M; Lachmann, V; Verde, PE; Zeus, T | 1 |
El Accaoui, R; Gnanaraj, J; Jayamani Roshan, S; Shetty, S | 1 |
Akçakaya, M; Chen, KA; Farzaneh-Far, A; Hughes, A; Kazmirczak, F; Martin, CM; Nijjar, PS; Okasha, O; Shenoy, C; Zhang, L | 1 |
Auerbach, A; Chan, N; Delphin, J; Kataria, V; Makaryus, JN | 1 |
Gandhi, H; Goldberg, Y; Hasani, A; Mustehsan, MH; Rashid, SMI | 1 |
Ahlberg, AW; Alter, EL; Duvall, WL; Felpel, KD; Gowdar, S; Henzlova, MJ; Perucki, WH; Rai, M; Savino, JA | 1 |
Cremer, PC; Harb, SC; Jaber, WA; Mentias, A; Meredith, D; Xu, B | 1 |
Chan, N; Kataria, V; Kim, BS; Makaryus, JN; Raimondi, P | 1 |
Evans, K; Farzaneh-Far, A; Kwong, RY; Romano, S; Romer, B; Shenoy, C; Trybula, M | 1 |
Belcik, JT; Davidson, BP; Fazio, S; Ferencik, M; Layoun, M; Lindner, JR; Moccetti, F; Raber, J; Taqui, S; Tavori, H; Turker, M | 1 |
Al Badarin, F; Bateman, TM; Case, JA; Chan, PS; Courter, S; Heller, GV; Kennedy, KF; McGhie, AI; Patel, KK; Spertus, JA | 1 |
Doan, TT; Loar, RW; Masand, PM; Noel, CV; Pednekar, AS; Wilkinson, JC | 1 |
Aulwes, D; Gupta, D; Holly, TA; Montero, K; Ross, MI; Shen, S; Wilkins, JT; Wu, E | 1 |
Ali, B; Ali, T; Blankstein, R; Bruyere, J; Di Carli, MF; Dorbala, S; Hsiao, E; Kwong, RY; Skali, H | 1 |
Bhave, NM; Cavanaugh, KP; Chandra, S; Czobor, P; Davidson, MH; Freed, BH; Lang, RM; Mor-Avi, V; Narang, A; Patel, AR; Tanaka, SM; Turner, KM; Zaran, ER | 1 |
Alam, M; Ananthasubramaniam, K; Boedeker, S; Brooks, K; Iyer, H; Khandelwal, A; Nguyen, P; Saad, H; Shaikh, K; Wang, DD | 1 |
Doukky, R; Golzar, Y | 1 |
Cohen, M; Dunn, T; Mooney, D; Rosenblatt, J | 1 |
Hage, FG | 1 |
Cerqueira, MD; Cremer, PC; Jaber, WA; Khalaf, S; Lou, J; Rodriguez, L | 1 |
Bayer, RR; De Cecco, CN; Harris, BS; Krazinski, AW; McWhite, CB; Meinel, FG; Schoepf, UJ; Silverman, JR | 1 |
Hage, FG; Iskandrian, AE | 1 |
Bateman, TM; Cerqueira, MD; Iskandrian, AE; Mahmarian, JJ; Nabi, F; Peterson, LE; Thomas, GS; Xu, J | 1 |
Amano, T; Doh, JH; Kato, D; Kim, HS; Koo, BK; Kurita, A; Lim, WH; Nam, CW; Oi, M; Park, JJ; Park, KW; Pijls, NH; Takashima, H; Toyofuku, M; van Nunen, L; Waseda, K; Yang, HM | 1 |
Bleich, S; El-Hajj, S; Ghimire, G; Hage, FG; Iskandrian, AE; Lester, D; Mckay, J | 1 |
Doukky, R; Dua, SG; Gidea, C; Golzar, J; Golzar, Y; Olusanya, A; Pe, N | 1 |
Borges-Neto, S; Dunning, A; Farzaneh-Far, A; O'Connor, CM; Oldan, JD; Shaw, LK | 1 |
AlJaroudi, WA; Bleich, S; El-Hajj, S; Farag, A; Hage, FG; Iskandrian, AE; Manaoragada, P | 1 |
Acampa, W; Anagnostopoulos, C; Ballinger, J; Bengel, F; Buechel, RR; Cuocolo, A; De Bondt, P; de Wit, TC; Flotats, A; Hacker, M; Hesse, B; Hindorf, C; Kaufmann, PA; Lindner, O; Ljungberg, M; Lonsdale, M; Manrique, A; Minarik, D; Scholte, AJ; Slart, RH; Trägårdh, E; van Eck-Smit, BL; Verberne, HJ | 1 |
Abdelmoneim, SS; Adolphson, M; Huang, R; Kirby, B; Mulvagh, SL; Nhola, LF; O'Leary, E; Omer, MA; Porter, TR; Warta, SJ; Xie, F | 1 |
Bonyadlou, S; Huang, HW; Mehra, A; Qamruddin, S; Yoon, AJ | 1 |
Bourque, JM; Löffler, AI | 1 |
Bordenave, L; Douard, H; Janvier, L; Karcher, G; Pinaquy, J | 1 |
Ali, A; Campagnoli, T; Doukky, R; Fughhi, I; Wassouf, M | 1 |
Reyes, E | 1 |
Aarøe, J; Eggert Jensen, S; Pape, M; Petersen, LJ; Zacho, HD | 1 |
AlJaroudi, WA; Andrikopoulou, E; Farag, A; Hage, FG; Iskandrian, AE; Lester, D; Patel, H | 1 |
Abdallah, M; Dwivedi, A; Gerson, MC; Jameria, ZA; Kalakota, N; Khaleghi, M; Khan, N; Washburn, E | 1 |
Berman, D; Brodov, Y; Fish, M; Gerlach, J; Germano, G; Gransar, H; Lemley, M; Otaki, Y; Rubeaux, M; Slomka, P | 1 |
Bauml, MA; Chung, J; Farzaneh-Far, A; Jue, J; McGraw, S; Romano, S | 1 |
Cascino, T; Corbett, JR; Ficaro, EP; Ghannam, M; Konerman, M; Lazarus, JJ; McLaughlin, VV; Mikhova, K; Moles, VM; Murthy, VL; Saleh, A; Weinberg, RL; Yun, HJ | 1 |
Ananthasubramaniam, K; Cullom, SJ; Feaheny, KM; Gropler, RJ; Jain, D; Kitt, TM; Thomas, GS; Thompson, RC | 1 |
Buhr, C; Eggebrecht, H; Erbel, R; Gössl, M | 1 |
Druz, RS | 1 |
Bateman, TM; Cerqueira, MD; Hendel, RC; Iskandrian, AE; Mahmarian, JJ; Moye, LA; Olmsted, AW; Thomas, GS | 1 |
Al Jaroudi, W; Iskandrian, AE | 1 |
Curran, MP; Garnock-Jones, KP | 1 |
Aljaroudi, W; Bhambhvani, P; Heo, J; Iqbal, F; Iskandrian, AE; Koneru, J | 1 |
Franks, B; Iskandrian, AE; McNutt, BE; Tejani, FH; Thompson, RC | 1 |
Ananthasubramaniam, K; Bukofzer, S; Feaheny, K; Klauke, B; McNutt, B; Weiss, R | 1 |
Ahmado, I; Flynn, J; Gurm, GS; Sidhu, MS; Uthamalingam, S | 1 |
Giedd, KN; Katz, JS; Rachko, M; Ruisi, M | 1 |
Frost, L; Hendel, RC | 1 |
Ahlberg, AW; Ardestani, A; Barmpouletos, D; Borer, SM; Cyr, G; Heller, GV; Iyah, GS; Katten, DM; Mathur, S; Morales, DC; Parker, MW; Slim, HB | 1 |
AlJaroudi, WA; Alraies, MC; Cerquiera, MD; Jaber, WA | 1 |
Ghimire, G; Hage, FG; Heo, J; Iskandrian, AE | 1 |
Al-Amoodi, M; Bateman, TM; Bybee, KA; Iain McGhie, A; Kennedy, KF; O'Keefe, JH; Oakes, L; Patil, H; Thomas, GS; Thompson, EC; Thompson, RC | 1 |
Boulanger, L; Friedman, M; Gatt, E; Kothari, S; Spalding, J; Wu, Y | 1 |
Cerqueira, MD | 1 |
Eggbrecht, H; Gössl, M | 1 |
9 review(s) available for regadenoson and Arteriosclerosis, Coronary
Article | Year |
---|---|
Comparison of regadenoson and nitroprusside to adenosine for measurement of fractional flow reserve: A systematic review and meta-analysis.
Topics: Administration, Intravenous; Adult; Aged; Cardiac Catheterization; Coronary Artery Disease; Coronary Stenosis; Coronary Vessels; Female; Fractional Flow Reserve, Myocardial; Humans; Hyperemia; Male; Middle Aged; Nitroprusside; Predictive Value of Tests; Purines; Pyrazoles; Reproducibility of Results; Severity of Illness Index; Vasodilator Agents | 2018 |
Incidence of atrioventricular block with vasodilator stress SPECT: A meta-analysis.
Topics: Adenosine; Aged; Atrioventricular Block; Coronary Artery Disease; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Reproducibility of Results; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2019 |
Regadenoson use in patients with chronic obstructive pulmonary disease: the state of current knowledge.
Topics: Adenosine A2 Receptor Agonists; Asthma; Coronary Artery Disease; Echocardiography, Stress; Exercise Test; Humans; Lung; Myocardial Perfusion Imaging; Patient Selection; Predictive Value of Tests; Prognosis; Pulmonary Disease, Chronic Obstructive; Purines; Pyrazoles; Risk Factors; Severity of Illness Index; Vasodilator Agents | 2014 |
Regadenoson stress for myocardial perfusion imaging.
Topics: Adenosine A2 Receptor Agonists; Coronary Artery Disease; Heart Function Tests; Humans; Myocardial Perfusion Imaging; Purines; Pyrazoles; Vasodilator Agents | 2016 |
Regadenoson in the detection of coronary artery disease.
Topics: Adenosine A2 Receptor Agonists; Animals; Contraindications; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Heart Function Tests; Humans; Hyperemia; Purines; Pyrazoles; Receptor, Adenosine A2A; Structure-Activity Relationship; Time Factors; Vasodilation; Vasodilator Agents | 2008 |
Current advances in vasodilator pharmacological stress perfusion imaging.
Topics: Adenosine; Adult; Contraindications; Coronary Artery Disease; Dipyridamole; Exercise Test; Female; Humans; Myocardial Perfusion Imaging; Purines; Pyrazoles; Radiopharmaceuticals; Vasodilator Agents | 2009 |
Regadenoson: a new myocardial stress agent.
Topics: Blood Pressure; Coronary Artery Disease; Exercise Test; Heart Rate; Humans; Myocardial Perfusion Imaging; Purines; Pyrazoles; Vasodilator Agents | 2009 |
Regadenoson: a focused update.
Topics: Coronary Artery Disease; Evidence-Based Medicine; Exercise Test; Humans; Myocardial Perfusion Imaging; Purines; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2013 |
The future of pharmacologic stress: selective A2A adenosine receptor agonists.
Topics: Adenosine A2 Receptor Agonists; Animals; Clinical Trials as Topic; Coronary Artery Disease; Coronary Circulation; Forecasting; Humans; Purines; Pyrazoles; Receptor, Adenosine A2A; Stress, Physiological; Vasodilation | 2004 |
13 trial(s) available for regadenoson and Arteriosclerosis, Coronary
Article | Year |
---|---|
The Feasibility, Tolerability, Safety, and Accuracy of Low-radiation Dynamic Computed Tomography Myocardial Perfusion Imaging With Regadenoson Compared With Single-photon Emission Computed Tomography.
Topics: Coronary Angiography; Coronary Artery Disease; Feasibility Studies; Female; Humans; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2021 |
Randomized Comparison of Clinical Effectiveness of Pharmacologic SPECT and PET MPI in Symptomatic CAD Patients.
Topics: Adult; Aged; Aged, 80 and over; Cardiovascular Agents; Comparative Effectiveness Research; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Coronary Stenosis; Dipyridamole; Female; Health Status; Humans; Kansas; Male; Middle Aged; Myocardial Perfusion Imaging; Myocardial Revascularization; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Prospective Studies; Purines; Pyrazoles; Referral and Consultation; Severity of Illness Index; Single Photon Emission Computed Tomography Computed Tomography; Time Factors; Treatment Outcome; Vasodilator Agents | 2019 |
Safety and feasibility of adjunctive regadenoson injection at peak exercise during exercise myocardial perfusion imaging: The Both Exercise and Regadenoson Stress Test (BERST) trial.
Topics: Adenosine A2 Receptor Agonists; Adult; Coronary Artery Disease; Exercise Test; Female; Humans; Image Enhancement; Male; Myocardial Perfusion Imaging; Physical Endurance; Physical Exertion; Purines; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2013 |
Stress positron emission tomography is safe and can guide coronary revascularization in high-risk patients being considered for transcatheter aortic valve replacement.
Topics: Aged; Aortic Valve Stenosis; Coronary Artery Disease; Exercise Test; Female; Humans; Male; Myocardial Perfusion Imaging; Percutaneous Coronary Intervention; Positron-Emission Tomography; Purines; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Surgery, Computer-Assisted; Transcatheter Aortic Valve Replacement; Vasodilator Agents | 2014 |
Regadenoson provides perfusion results comparable to adenosine in heterogeneous patient populations: a quantitative analysis from the ADVANCE MPI trials.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Aged; Coronary Artery Disease; Double-Blind Method; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Stroke Volume; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents; Ventricular Dysfunction, Left | 2015 |
A useful and easy to develop combined stress test for myocardial perfusion imaging: Regadenoson and isometric exercise, preliminary results.
Topics: Aged; Coronary Artery Disease; Exercise Test; Female; Hand Strength; Humans; Image Enhancement; Isometric Contraction; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2017 |
The EXERRT trial: "EXErcise to Regadenoson in Recovery Trial": A phase 3b, open-label, parallel group, randomized, multicenter study to assess regadenoson administration following an inadequate exercise stress test as compared to regadenoson without exerc
Topics: Coronary Artery Disease; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Recovery of Function; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; United States; Vasodilator Agents | 2017 |
Regadenoson induces comparable left ventricular perfusion defects as adenosine: a quantitative analysis from the ADVANCE MPI 2 trial.
Topics: Adenosine; Coronary Artery Disease; Coronary Circulation; Double-Blind Method; Heart Ventricles; Humans; Infusions, Intravenous; Linear Models; Myocardial Ischemia; Myocardial Perfusion Imaging; Predictive Value of Tests; Prospective Studies; Purines; Pyrazoles; Severity of Illness Index; Stroke Volume; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents; Ventricular Dysfunction, Left | 2009 |
Safety of regadenoson in patients with end-stage liver disease.
Topics: Adenosine A2 Receptor Antagonists; Aged; Comorbidity; Coronary Artery Disease; Drug-Related Side Effects and Adverse Reactions; Exercise Test; Female; Humans; Liver Diseases; Male; Ohio; Purines; Pyrazoles; Radionuclide Imaging; Risk Assessment; Risk Factors; Survival Analysis; Survival Rate; Terminally Ill; Vasodilator Agents | 2011 |
Effect of caffeine on SPECT myocardial perfusion imaging during regadenoson pharmacologic stress: rationale and design of a prospective, randomized, multicenter study.
Topics: Adenosine A2 Receptor Antagonists; Administration, Oral; Adult; Aged; Aged, 80 and over; Caffeine; Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography; Central Nervous System Stimulants; Coronary Artery Disease; Dose-Response Relationship, Drug; Drug Interactions; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Prevalence; Prospective Studies; Purines; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; United States; Young Adult | 2011 |
A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.
Topics: Adenosine A2 Receptor Antagonists; Adult; Aged; Aged, 80 and over; Comorbidity; Coronary Artery Disease; Double-Blind Method; Drug Tolerance; Drug-Related Side Effects and Adverse Reactions; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Placebo Effect; Prevalence; Purines; Pyrazoles; Radionuclide Imaging; Risk Assessment; Risk Factors; United States; Young Adult | 2012 |
A strategy of symptom-limited exercise with regadenoson-as-needed for stress myocardial perfusion imaging: a randomized controlled trial.
Topics: Adenosine A2 Receptor Agonists; Coronary Artery Disease; Exercise Test; Female; Humans; Image Enhancement; Male; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2013 |
Regadenoson pharmacologic stress for myocardial perfusion imaging: a three-way comparison between regadenoson administered at peak exercise, during walk recovery, or no-exercise.
Topics: Adenosine A2 Receptor Agonists; Coronary Artery Disease; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Physical Endurance; Prevalence; Purines; Pyrazoles; Reproducibility of Results; Rest; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents; Walking | 2013 |
60 other study(ies) available for regadenoson and Arteriosclerosis, Coronary
Article | Year |
---|---|
Splenic switch-off in regadenoson
Topics: Coronary Artery Disease; Female; Humans; Male; Myocardial Perfusion Imaging; Positron-Emission Tomography; Purines; Rubidium Radioisotopes | 2023 |
Regadenoson Is All the RAGE: Targeting the Inflammatory Cascade in Primary Graft Dysfunction.
Topics: Coronary Artery Disease; Humans; Primary Graft Dysfunction; Purines; Vasodilator Agents | 2023 |
PET myocardial perfusion imaging of regadenoson-induced coronary vasospasm.
Topics: Coronary Artery Disease; Coronary Vasospasm; Humans; Myocardial Perfusion Imaging; Purines; Tomography, Emission-Computed, Single-Photon | 2023 |
What is this image? 2023 image 2 results: In vivo demonstration of regadenoson-induced severe ischemia on PET myocardial perfusion imaging in a patient with hypertrophic obstructive cardiomyopathy and nonobstructive coronary artery disease.
Topics: Cardiomyopathy, Hypertrophic; Coronary Artery Disease; Humans; Ischemia; Myocardial Perfusion Imaging | 2023 |
Feasibility and accuracy of SPECT myocardial perfusion imaging in end-stage lung disease.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Cross-Sectional Studies; Feasibility Studies; Female; Humans; Lung Neoplasms; Male; Middle Aged; Myocardial Perfusion Imaging; Percutaneous Coronary Intervention; Purines; Pyrazoles; Reproducibility of Results; Retrospective Studies; Tomography, Emission-Computed, Single-Photon | 2020 |
Are Patients With End-Stage Liver Disease Maximally Vasodilated?: Insights From Rubidium-82 PET Dilatory Perfusion.
Topics: Aged; Coronary Artery Disease; Dipyridamole; End Stage Liver Disease; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Positron Emission Tomography Computed Tomography; Predictive Value of Tests; Purines; Pyrazoles; Radiopharmaceuticals; Retrospective Studies; Rubidium Radioisotopes; Vasodilation; Vasodilator Agents | 2019 |
Regadenoson myocardial perfusion scintigraphy for the evaluation of coronary artery disease in patients with lung disease: A series of five cases.
Topics: Adenosine A2 Receptor Agonists; Aged; Coronary Artery Disease; Female; Humans; Lung Diseases; Male; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon | 2020 |
Safety of regadenoson with theophylline reversal during dynamic computed tomography perfusion and magnetic resonance imaging in patients with coronary artery disease.
Topics: Coronary Artery Disease; Female; Humans; Magnetic Resonance Imaging; Myocardial Perfusion Imaging; Perfusion; Prospective Studies; Purines; Pyrazoles; Theophylline; Tomography, Emission-Computed, Single-Photon | 2020 |
Regadenoson-induced T-wave heterogeneity complements coronary stenosis detection by myocardial perfusion imaging in men and women.
Topics: Coronary Angiography; Coronary Artery Disease; Coronary Stenosis; Female; Humans; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles | 2021 |
The prognostic implications of ST-segment and T-wave abnormalities in patients undergoing regadenoson stress SPECT myocardial perfusion imaging.
Topics: Coronary Artery Disease; Humans; Myocardial Ischemia; Myocardial Perfusion Imaging; Prognosis; Purines; Pyrazoles; Retrospective Studies; Tomography, Emission-Computed, Single-Photon | 2022 |
Quantitative myocardial perfusion response to adenosine and regadenoson in patients with suspected coronary artery disease.
Topics: Adenosine; Arteries; Coronary Artery Disease; Coronary Circulation; Humans; Hyperemia; Myocardial Perfusion Imaging; Perfusion; Positron-Emission Tomography; Purines; Pyrazoles; Water | 2022 |
Left ventricular ejection fraction, myocardial blood flow and hemodynamic variables in adenosine and regadenoson vasodilator 82-Rubidium PET.
Topics: Adenosine; Coronary Artery Disease; Coronary Circulation; Hemodynamics; Humans; Myocardial Perfusion Imaging; Positron-Emission Tomography; Purines; Pyrazoles; Rubidium; Stroke Volume; Vasodilator Agents; Ventricular Function, Left | 2022 |
Clinical experience with regadenoson SPECT myocardial perfusion imaging: insights into patient characteristics, safety, and impact of results on clinical management.
Topics: Adolescent; Aged; Coronary Artery Disease; Exercise Test; Female; Humans; Male; Myocardial Perfusion Imaging; Perfusion; Predictive Value of Tests; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon | 2022 |
Rapid rest/stress regadenoson ungated perfusion CMR for detection of coronary artery disease in patients with atrial fibrillation.
Topics: Aged; Aged, 80 and over; Atrial Fibrillation; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Female; Heart Rate; Humans; Hyperemia; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Perfusion Imaging; Predictive Value of Tests; Purines; Pyrazoles; Reproducibility of Results; Time Factors; Vasodilator Agents | 2017 |
Effects of caffeine intake prior to stress cardiac magnetic resonance perfusion imaging on regadenoson- versus adenosine-induced hyperemia as measured by T1 mapping.
Topics: Adenosine; Aged; Caffeine; Coffee; Coronary Artery Disease; Coronary Circulation; Female; Humans; Hyperemia; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Perfusion Imaging; Predictive Value of Tests; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Purines; Pyrazoles; Reproducibility of Results; Time Factors; Vasodilator Agents | 2017 |
Quantitative cardiovascular magnetic resonance perfusion imaging identifies reduced flow reserve in microvascular coronary artery disease.
Topics: Adult; Aged; Blood Flow Velocity; Case-Control Studies; Computed Tomography Angiography; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Coronary Vessels; Female; Fractional Flow Reserve, Myocardial; Humans; Magnetic Resonance Imaging, Cine; Male; Microcirculation; Middle Aged; Myocardial Perfusion Imaging; Predictive Value of Tests; Purines; Pyrazoles; Vasodilator Agents | 2018 |
CMR stress testing in a patient with morbid obesity (BMI 58 kg/m
Topics: Body Mass Index; Coronary Artery Disease; Coronary Circulation; Coronary Stenosis; Female; Humans; Magnetic Resonance Imaging; Middle Aged; Myocardial Perfusion Imaging; Obesity, Morbid; Predictive Value of Tests; Prognosis; Purines; Pyrazoles; Risk Factors; Vasodilator Agents | 2018 |
Fully quantitative pixel-wise analysis of cardiovascular magnetic resonance perfusion improves discrimination of dark rim artifact from perfusion defects associated with epicardial coronary stenosis.
Topics: Adult; Aged; Artifacts; Blood Flow Velocity; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Coronary Stenosis; Coronary Vessels; Female; Humans; Image Interpretation, Computer-Assisted; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Perfusion Imaging; Predictive Value of Tests; Purines; Pyrazoles; Reproducibility of Results; Retrospective Studies; Severity of Illness Index; Vasodilator Agents | 2018 |
Relationship of
Topics: Aged; Algorithms; Angiography; Area Under Curve; Constriction, Pathologic; Coronary Angiography; Coronary Artery Disease; Coronary Circulation; Female; Heart; Heart Ventricles; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Myocardium; Positron Emission Tomography Computed Tomography; Purines; Pyrazoles; Retrospective Studies; Rubidium Radioisotopes | 2020 |
Feasibility, safety and effectiveness in measuring microvascular resistance with regadenoson.
Topics: Adenosine A2 Receptor Agonists; Aged; Coronary Artery Disease; Feasibility Studies; Female; Fractional Flow Reserve, Myocardial; Humans; Male; Microcirculation; Purines; Pyrazoles | 2019 |
Pituitary apoplexy after regadenoson myocardial perfusion scan.
Topics: Adenosine A2 Receptor Agonists; Coronary Artery Disease; Female; Humans; Middle Aged; Myocardial Perfusion Imaging; Pituitary Apoplexy; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon | 2020 |
Safety and prognostic value of regadenoson stress cardiovascular magnetic resonance imaging in heart transplant recipients.
Topics: Adult; Coronary Artery Disease; Female; Heart Transplantation; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Myocardial Infarction; Percutaneous Coronary Intervention; Predictive Value of Tests; Purines; Pyrazoles; Reoperation; Retrospective Studies; Risk Factors; Treatment Outcome; Vasodilator Agents | 2019 |
Marked multi-distribution myocardial ischemia in a patient with hypertrophic cardiomyopathy and no obstructive coronary artery disease.
Topics: Cardiac Catheterization; Cardiomyopathy, Hypertrophic; Coronary Artery Disease; Electrocardiography; Female; Humans; Middle Aged; Myocardial Ischemia; Myocardial Perfusion Imaging; Purines; Pyrazoles; Systole; Tomography, Emission-Computed, Single-Photon; Ventricular Function, Left | 2020 |
Regadenoson-induced asystole and ischemic EKG changes in the setting of underlying coronary disease.
Topics: Aged; Bradycardia; Cardiology; Coronary Artery Disease; Echocardiography; Heart Arrest; Hemodynamics; Humans; Ischemia; Male; Purines; Pyrazoles | 2020 |
Risk stratification with vasodilator stress SPECT myocardial perfusion imaging in patients with elevated cardiac biomarkers.
Topics: Aged; Biomarkers; Coronary Artery Disease; Exercise Test; Female; Heart Failure; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Myocardial Perfusion Imaging; Perfusion; Prognosis; Proportional Hazards Models; Purines; Pyrazoles; Risk Assessment; Tomography, Emission-Computed, Single-Photon; Treatment Outcome; Vasodilator Agents | 2020 |
Initial experience with regadenoson stress positron emission tomography in patients with left bundle branch block: Low prevalence of septal defects and high accuracy for obstructive coronary artery disease.
Topics: Aged; Aged, 80 and over; Bundle-Branch Block; Coronary Artery Disease; Female; Heart Septum; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Positron-Emission Tomography; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon | 2021 |
Marked ST-segment elevations during regadenoson pharmacologic nuclear stress testing.
Topics: Aged; Angioplasty, Balloon; Coronary Angiography; Coronary Artery Disease; Electrocardiography; Exercise Test; Humans; Male; Myocardial Ischemia; Myocardial Perfusion Imaging; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon | 2020 |
Prognostic Implications of Blunted Feature-Tracking Global Longitudinal Strain During Vasodilator Cardiovascular Magnetic Resonance Stress Imaging.
Topics: Aged; Coronary Artery Disease; Coronary Circulation; Female; Humans; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Observer Variation; Predictive Value of Tests; Progression-Free Survival; Prospective Studies; Purines; Pyrazoles; Reproducibility of Results; Risk Assessment; Risk Factors; Stroke Volume; Time Factors; Vasodilation; Vasodilator Agents; Ventricular Function, Left | 2020 |
Coronary Microvascular Dysfunction by Myocardial Contrast Echocardiography in Nonelderly Patients Referred for Computed Tomographic Coronary Angiography.
Topics: Adult; Brachial Artery; Chest Pain; Computed Tomography Angiography; Coronary Artery Disease; Echocardiography; Female; Humans; Iohexol; Male; Microvascular Angina; Middle Aged; Oregon; Prospective Studies; Purines; Pyrazoles | 2019 |
Regadenoson Stress Perfusion Cardiac Magnetic Resonance Imaging in Children With Kawasaki Disease and Coronary Artery Disease.
Topics: Adenosine A2 Receptor Agonists; Adolescent; Child; Child, Preschool; Coronary Artery Disease; Cross-Sectional Studies; Female; Humans; Infant; Magnetic Resonance Imaging; Male; Mucocutaneous Lymph Node Syndrome; Myocardial Perfusion Imaging; Purines; Pyrazoles; Retrospective Studies | 2019 |
Detection of obstructive coronary artery disease using regadenoson stress and 82Rb PET/CT myocardial perfusion imaging.
Topics: Aged; Coronary Angiography; Coronary Artery Disease; Humans; Male; Middle Aged; Multimodal Imaging; Myocardial Perfusion Imaging; Positron-Emission Tomography; Purines; Pyrazoles; Rubidium Radioisotopes; Stress, Physiological; Stroke Volume; Tomography, X-Ray Computed; Vasodilator Agents; Ventricular Dysfunction, Left | 2013 |
Prognostic value of normal regadenoson stress perfusion cardiovascular magnetic resonance.
Topics: Adult; Aged; Contrast Media; Coronary Artery Disease; Female; Gadolinium DTPA; Hemodynamics; Humans; Infusions, Intravenous; Kaplan-Meier Estimate; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Myocardial Revascularization; Perfusion; Predictive Value of Tests; Prognosis; Purines; Pyrazoles; Risk Factors; Stroke Volume; Time Factors; Vasodilator Agents; Ventricular Function, Left | 2013 |
Feasibility, safety and accuracy of regadenoson-atropine (REGAT) stress echocardiography for the diagnosis of coronary artery disease: an angiographic correlative study.
Topics: Adenosine A2 Receptor Agonists; Anti-Arrhythmia Agents; Atropine; Coronary Angiography; Coronary Artery Disease; Dyspnea; Echocardiography, Stress; Feasibility Studies; Female; Headache; Humans; Male; Middle Aged; Patient Satisfaction; Predictive Value of Tests; Prospective Studies; Purines; Pyrazoles; Reproducibility of Results; Sensitivity and Specificity; Surveys and Questionnaires | 2014 |
Asystole following regadenoson infusion in stable outpatients.
Topics: Adenosine A2 Receptor Agonists; Aged; Ambulatory Care; Coronary Artery Disease; Exercise Test; Female; Heart Arrest; Humans; Infusions, Intravenous; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles; Vasodilator Agents | 2014 |
Regadenoson for myocardial perfusion imaging: Is it safe?
Topics: Adenosine A2 Receptor Agonists; Coronary Artery Disease; Exercise Test; Female; Heart Arrest; Humans; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles; Vasodilator Agents | 2014 |
Incremental value of pharmacological stress cardiac dual-energy CT over coronary CT angiography alone for the assessment of coronary artery disease in a high-risk population.
Topics: Adenosine; Cardiac Catheterization; Cardiac-Gated Imaging Techniques; Contrast Media; Coronary Angiography; Coronary Artery Disease; Exercise Test; Female; Humans; Iopamidol; Male; Middle Aged; Prospective Studies; Purines; Pyrazoles; Radiation Dosage; Radiographic Image Interpretation, Computer-Assisted; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed | 2014 |
Serious complications associated with regadenoson administration for myocardial perfusion imaging: a commentary.
Topics: Adenosine A2 Receptor Agonists; Atropine; Bradycardia; Coronary Artery Disease; Exercise Test; Female; Heart Arrest; Humans; Hypotension; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles; Vasodilator Agents | 2014 |
Variability of fractional flow reserve according to the methods of hyperemia induction.
Topics: Adenosine; Aged; Coronary Artery Disease; Coronary Circulation; Female; Fractional Flow Reserve, Myocardial; Hemodynamics; Humans; Hyperemia; Infusions, Intra-Arterial; Infusions, Intravenous; Male; Middle Aged; Nicorandil; Purines; Pyrazoles; Radiography; Reproducibility of Results; Vasodilator Agents | 2015 |
The prognostic value of regadenoson myocardial perfusion imaging.
Topics: Adenosine A2 Receptor Agonists; Coronary Artery Disease; Death, Sudden, Cardiac; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Prevalence; Prognosis; Purines; Pyrazoles; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Survival Rate; Tomography, Emission-Computed, Single-Photon; United States | 2015 |
The significance of automatically measured transient ischemic dilation in identifying severe and extensive coronary artery disease in regadenoson, single-isotope technetium-99m myocardial perfusion SPECT.
Topics: Aged; Cohort Studies; Coronary Angiography; Coronary Artery Disease; Exercise Test; Female; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Myocardial Perfusion Imaging; Pattern Recognition, Automated; Prevalence; Purines; Pyrazoles; Radiopharmaceuticals; Regression Analysis; Reproducibility of Results; Rest; ROC Curve; Technetium; Tomography, Emission-Computed, Single-Photon | 2015 |
Comparison of the prognostic value of regadenoson and adenosine myocardial perfusion imaging.
Topics: Adenosine; Coronary Artery Disease; Death, Sudden, Cardiac; Exercise Test; Female; Humans; Incidence; Male; Middle Aged; Myocardial Perfusion Imaging; North Carolina; Prevalence; Prognosis; Purines; Pyrazoles; Reproducibility of Results; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Survival Analysis; Vasodilator Agents | 2015 |
Effect of changes in perfusion defect size during serial regadenoson myocardial perfusion imaging on cardiovascular outcomes in high-risk patients.
Topics: Alabama; Comorbidity; Contrast Media; Coronary Artery Disease; Exercise Test; Female; Humans; Image Interpretation, Computer-Assisted; Male; Middle Aged; Myocardial Infarction; Myocardial Perfusion Imaging; Percutaneous Coronary Intervention; Prevalence; Prognosis; Purines; Pyrazoles; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Survival Rate; Vasodilator Agents | 2016 |
EANM procedural guidelines for radionuclide myocardial perfusion imaging with SPECT and SPECT/CT: 2015 revision.
Topics: Adult; Contrast Media; Coronary Artery Disease; Dose-Response Relationship, Drug; Exercise; Humans; Image Processing, Computer-Assisted; Male; Middle Aged; Multimodal Imaging; Myocardial Perfusion Imaging; Practice Guidelines as Topic; Purines; Pyrazoles; Radiation Exposure; Safety; Societies, Medical; Software; Tomography, X-Ray Computed; Vasodilator Agents | 2015 |
Regadenoson Stress Real-Time Myocardial Perfusion Echocardiography for Detection of Coronary Artery Disease: Feasibility and Accuracy of Two Different Ultrasound Contrast Agents.
Topics: Adenosine A2 Receptor Agonists; Contrast Media; Coronary Angiography; Coronary Artery Disease; Echocardiography, Stress; Feasibility Studies; Female; Humans; Injections, Intravenous; Male; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Reproducibility of Results | 2015 |
ST Segment Elevation ECG Changes During Pharmacologic Stress With Regadenoson.
Topics: Adenosine A2 Receptor Agonists; Coronary Angiography; Coronary Artery Disease; Electrocardiography; Exercise Test; Heart Rate; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon | 2016 |
Prognostic impact of TID in regadenoson MPI: Some patients and certain events.
Topics: Coronary Artery Disease; Exercise Test; Humans; Myocardial Perfusion Imaging; Prognosis; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon | 2016 |
The prognostic value of regadenoson SPECT myocardial perfusion imaging in patients with end-stage renal disease.
Topics: Age Distribution; Cardio-Renal Syndrome; Chicago; Comorbidity; Coronary Artery Disease; Death, Sudden, Cardiac; Exercise Test; Female; Humans; Incidence; Kidney Failure, Chronic; Male; Middle Aged; Myocardial Perfusion Imaging; Prognosis; Purines; Pyrazoles; Reproducibility of Results; Risk Assessment; Sensitivity and Specificity; Sex Distribution; Single-Blind Method; Survival Rate; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2017 |
Safety and tolerability of regadenoson for myocardial perfusion imaging - first Danish experience.
Topics: Adenosine A2 Receptor Agonists; Aged; Coronary Artery Disease; Denmark; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Exercise Test; Female; Hemodynamics; Humans; Male; Middle Aged; Outcome and Process Assessment, Health Care; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon | 2016 |
The reproducibility and prognostic value of serial measurements of heart rate response to regadenoson during myocardial perfusion imaging.
Topics: Coronary Artery Disease; Female; Heart Rate; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Prognosis; Purines; Pyrazoles; Reproducibility of Results; Time Factors; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2016 |
Computer derived transient ischemic dilation ratio for identifying extensive coronary artery disease using a CZT camera and imaging in the upright position.
Topics: Aged; Cadmium; Cohort Studies; Coronary Angiography; Coronary Artery Disease; Diagnosis, Computer-Assisted; Dilatation; Exercise Test; Female; Heart Ventricles; Humans; Image Processing, Computer-Assisted; Ischemia; Male; Middle Aged; Myocardial Perfusion Imaging; Predictive Value of Tests; Purines; Pyrazoles; Retrospective Studies; ROC Curve; Sensitivity and Specificity; Tellurium; Tomography, Emission-Computed, Single-Photon; Zinc | 2017 |
Quantitation of left ventricular ejection fraction reserve from early gated regadenoson stress Tc-99m high-efficiency SPECT.
Topics: Aged; Cardiac-Gated Single-Photon Emission Computer-Assisted Tomography; Coronary Artery Disease; Exercise Test; Female; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Male; Purines; Pyrazoles; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Stroke Volume; Technetium Tc 99m Sestamibi; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents; Ventricular Dysfunction, Left | 2016 |
Impact of Stress Cardiac Magnetic Resonance Imaging on Clinical Care.
Topics: Adenosine A2 Receptor Agonists; Aged; Aminophylline; Cardiotonic Agents; Clinical Decision-Making; Contrast Media; Coronary Artery Disease; Disease Management; Exercise Test; Female; Gadolinium; Heterocyclic Compounds; Humans; Logistic Models; Magnetic Resonance Imaging; Magnetic Resonance Imaging, Cine; Male; Middle Aged; Multivariate Analysis; Myocardial Ischemia; Myocardial Perfusion Imaging; Odds Ratio; Organometallic Compounds; Patient Selection; Prospective Studies; Purines; Pyrazoles | 2016 |
Safety of regadenoson stress testing in patients with pulmonary hypertension.
Topics: Adenosine A2 Receptor Agonists; Aged; Blood Pressure; Coronary Artery Disease; Dyspnea; Electrocardiography; Exercise Test; Female; Heart Rate; Humans; Hypertension, Pulmonary; Male; Middle Aged; Myocardial Perfusion Imaging; Positron-Emission Tomography; Purines; Pyrazoles; Retrospective Studies; Tomography, Emission-Computed, Single-Photon | 2018 |
Regadenoson.
Topics: Adenosine; Adenosine A2 Receptor Agonists; Animals; Coronary Artery Disease; Coronary Circulation; Humans; Myocardial Perfusion Imaging; Purines; Pyrazoles | 2010 |
Outcome of patients with regadenoson-induced ST-segment depression but normal perfusion on single-photon emission computed tomography.
Topics: Aged; Aged, 80 and over; Coronary Artery Disease; Electrocardiography; Exercise Test; Female; Follow-Up Studies; Humans; Male; Myocardial Perfusion Imaging; Prognosis; Purines; Pyrazoles; Risk Assessment; Survival Rate; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2013 |
Assessment of transient ischemic dilation (TID) ratio in gated SPECT myocardial perfusion imaging (MPI) using regadenoson, a new agent for pharmacologic stress testing.
Topics: Adenosine A2 Receptor Agonists; Aged; Aged, 80 and over; Angiography; Coronary Angiography; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Myocardial Perfusion Imaging; Odds Ratio; Purines; Pyrazoles; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Software; Tomography, Emission-Computed, Single-Photon | 2012 |
Off-label, but on-target: use of regadenoson with exercise.
Topics: Coronary Artery Disease; Exercise Test; Female; Humans; Image Enhancement; Male; Myocardial Perfusion Imaging; Purines; Pyrazoles; Tomography, Emission-Computed, Single-Photon | 2013 |
Safety and tolerability of regadenoson in 514 SPECT MPI patients with and without coronary artery disease and submaximal exercise heart rate response.
Topics: Cohort Studies; Coronary Artery Disease; Exercise Test; Female; Heart Rate; Hemodynamics; Humans; Male; Middle Aged; Myocardial Perfusion Imaging; Purines; Pyrazoles; Retrospective Studies; Safety; Tomography, Emission-Computed, Single-Photon; Treatment Outcome | 2013 |
Myocardial perfusion imaging laboratory efficiency with the use of regadenoson compared to adenosine and dipyridamole.
Topics: Adenosine; Coronary Artery Disease; Data Collection; Dipyridamole; Health Personnel; Humans; Myocardial Perfusion Imaging; Nuclear Medicine Department, Hospital; Purines; Pyrazoles; Receptor, Adenosine A2A; Time Factors; Tomography, Emission-Computed, Single-Photon; Vasodilator Agents | 2013 |
Regadenoson (CV Therapeutics/Astellas).
Topics: Adenosine A2 Receptor Agonists; Clinical Trials, Phase III as Topic; Coronary Artery Disease; Humans; Purines; Pyrazoles; Sensitivity and Specificity; Tomography, Emission-Computed, Single-Photon; Vasodilation; Vasodilator Agents | 2006 |